Nintedanib (n = 238) | Placebo (n = 86) | |
---|---|---|
Number of diarrhea events | ||
1 | 112 (47.1) | 70 (81.4) |
2 | 46 (19.3) | 11 (12.8) |
3 | 42 (17.6) | 2 (2.3) |
≥ 4 | 38 (16.0) | 3 (3.5) |
Time to onset of first diarrhea event (days) | ||
≤ 31 | 114 (47.9) | 41 (47.7) |
> 31 to ≤ 61 | 22 (9.2) | 13 (15.1) |
> 61 to ≤ 91 | 21 (8.8) | 6 (7.0) |
> 91 to ≤ 182 | 35 (14.7) | 8 (9.3) |
> 182 | 46 (19.3) | 18 (20.9) |
CTCAE grade of worst diarrhea event | ||
1 (mild) | 149 (62.6) | 70 (81.4) |
2 (moderate) | 60 (25.2) | 10 (11.6) |
3 (severe) | 29 (12.2) | 6 (7.0) |
≥ 4 (life-threatening/fatal) | 0 | 0 |
Worst consequence of diarrhea event for trial druga | ||
Dose reduction | 59 (24.8) | 3 (3.5) |
Discontinued trial drug | 21 (8.8) | 1 (1.2) |
Neither of above | 158 (66.4) | 82 (95.3) |